W. L. Gore & Associates, Inc. (Gore) has announced that the first
implants occurred in Europe to restore blood flow to peripheral arteries
using the GORE® VIABAHN® VBX Balloon Expandable
Endoprosthesis (VBX Stent Graft). The new device is designed for use in
the treatment of iliac occlusive disease and also during endovascular
aneurysmal repair. The first patients were treated at St. Franziskus
Hospital in Münster, Germany.

“We are continuing to elevate and enhance our cardiovascular care
offerings with this new technology that more reliably treats peripheral
arteries in a minimally invasive way,” said Giovanni Torsello, MD,
Professor and Chief of the Department of Vascular Surgery, St.
Franziskus Hospital. “The VBX Stent Graft demonstrates a notable, unique
combination of technical features beneficial in a broad range of vessels
with complex anatomy. Flexibility and accuracy are clearly noticeable.
In addition, the VBX Stent Graft provides precise delivery that we can
rely on.”

PROCEDURAL SUMMARY

The physicians at St. Franziskus Hospital are among a select group of
leaders in their field who have been first in Europe to provide the VBX
Stent Graft to patients. The VBX Stent Graft recently received CE mark
approval and is indicated for endovascular grafting of peripheral
vessels.

The patients who received the VBX Stent Grafts presented with iliac
occlusive disease and also complex aortic aneurysms treated with
branched aortic endograft (BEVAR).

AVAILABILITY

The VBX Stent Graft was developed utilizing the small diameter, ePTFE
stent graft technology from the GORE® VIABAHN®
Endoprosthesis. The VBX Stent Graft is configured in a range of
diameters from 5 to 11 millimeters and lengths of 15, 19, 29, 39, 59,
and 79 millimeters to cover a wide variety of treatment needs. The VBX
Stent Graft does not require pre-dilation, which reduces the number of
balloons required, and the longer lengths reduce the need to use
multiple stents for extensive lesions, both of which also contribute to
procedural cost savings.

“The VBX Stent Graft combines an implant with radial strength and
conformability to the anatomy along with a trackable delivery system
that results in successful outcomes for patients, providers, and
physicians,” said Eric Zacharias, Vascular Business Leader. “We look
forward to introducing the VBX Stent Graft throughout Europe during
2018.”

Gore provides a portfolio of peripheral vascular solutions that are
designed and tested for physicians to more reliably treat patients with
a wide range of challenging peripheral disease presentations and improve
those patients’ outcomes.* Each interventional solution is engineered
for durability, accuracy, thromboresistance, and conformability, and is
backed by dedicated service to help improve patient outcomes.

* For complete indications and other important safety information for
Gore commercial products referenced herein, refer to the applicable
Instructions for Use (IFU).

MEDICAL PRODUCTS DIVISION

Gore Medical Products Division engineers devices that treat a range of
cardiovascular and other health conditions. With more than 40 million
medical devices implanted over the course of more than 40 years, Gore
builds on its legacy of improving patient outcomes through research,
education and quality initiatives. Product performance, ease of use and
quality of service provide sustainable cost savings for physicians,
hospitals and insurers. Gore is joined in service with clinicians and
through this collaboration we are improving lives. www.goremedical.com

ABOUT GORE

W. L. Gore & Associates is a global materials science company dedicated
to transforming industries and improving lives. Founded in 1958, Gore
has built a reputation for solving complex technical challenges in the
most demanding environments — from revolutionizing the outerwear
industry with GORE-TEX® fabric to creating medical devices
that improve and save lives to enabling new levels of performance in the
aerospace, pharmaceutical and mobile electronics markets, among other
industries. The company is also known for its strong, team-oriented
culture and continued recognition from the Great Place to Work®
Institute. Headquartered in Newark, Del., Gore employs approximately
9,500 Associates and generates annual revenues that exceed $3 billion. www.gore.com

Products listed may not be available in all markets. GORE®,
VBX, and VIABAHN® are trademarks of W. L. Gore & Associates.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.